Pharmaxis Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PMXSF research report →
About the company
Pharmaxis Ltd, an Australian biopharmaceutical company established in 1998 and headquartered in Frenchs Forest, specializes in the global research, development, and commercialization of therapeutic products for fibrotic and inflammatory diseases. Its business is organized into two main divisions: the Mannitol Respiratory Business and New Drug Development. The company currently markets Bronchitol, an inhaled dry powder medication for the treatment of cystic fibrosis, and Aridol, a diagnostic tool used to detect hyper-responsive airways and assist in the diagnosis and management of asthma.
- CEO
- Gary Jonathan Phillips
- IPO
- 2010
- Employees
- 27
- HQ
- Frenchs Forest, NSW, AU
Price Chart
- Market Cap
- $31.04M
- P/E
- -4.34
- P/S
- 0.00
- P/B
- 2.11
- EV/EBITDA
- -1.63
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -61.92%
- ROIC
- -122.77%
- Revenue
- $0 · 0.00%
- Net Income
- $-7,919,000 · 47.70%
- EPS
- $-0.00 · 75.34%
- Op Income
- $-19,874,000
- FCF YoY
- 23.29%
- 52W High
- $0.03
- 52W Low
- $0.03
- 50D MA
- $0.03
- 200D MA
- $0.03
- Beta
- 0.27
- Avg Volume
- 98.28K
Get TickerSpark's AI analysis on PMXSF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our PMXSF coverage
Recent articles, reports, and earnings notes.
No research on PMXSF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PMXSF report →Similar companies
Peers in the same neighborhood.